Chronic Kidney Disease Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Chronic Kidney Disease market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as ProKidney, Reata Pharmaceuticals, Inc.,Novo Nordisk A/S, Boehringer Ingelheim,Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc, Lexicon Pharmaceuticals, Sanofi

[Nevada, United States] - DelveInsight's "Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Chronic Kidney Disease, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Chronic Kidney Disease Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Chronic Kidney Disease Market Report:
• The Chronic Kidney Disease market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Bayer announced that BAY3283142 is a new drug that is being developed to treat people with CKD. It works by activating a protein that helps relax blood vessels and is thought to have beneficial effects in CKD. In this study, researchers want to learn about how well different doses of BAY3283142 work when taken with standard treatment for CKD in reducing albumin in the urine of participants with CKD.
• In October, 2024: Boehringer Ingelheim announced that the aim of their study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease.
• In September, 2024: Boehringer Ingelheim announced that their study is open to adults who have kidney disease that is not caused by diabetes. The purpose of the study is to find out whether a medicine called avenciguat (BI 685509) improves kidney function. Three different doses of avenciguat are tested in this study.
• In September, 2024: AstraZeneca announced that their study will describe the efficacy and safety information with dapagliflozin in Chinese patients with chronic kidney disease.
• Among the 7MM, the US accounted for the highest prevalent cases of Anemia in Chronic Disease.
• In 2023, the US accounted for the highest number of treated cases of Anemia in Chronic Disease.
• Higher prevalence was seen in those older than 60 years, as compared with those age less than 60 years in the US in 2023.
• In patients with chronic kidney disease (CKD), the risk of developing anemia is 30% higher in males than in females.
• Key Chronic Kidney Disease Companies are as follows: ProKidney, Reata Pharmaceuticals, Inc.,Novo Nordisk A/S, Boehringer Ingelheim,Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc, Lexicon Pharmaceuticals, Sanofi
• Key Chronic Kidney Disease Therapies are as follow: MK0954, epoetin, PF-00489791, Fragmin, OPC-41061, Renamezin, sitagliptin, glipizide, cinacalcet, HD-003, Atrasentan, Everolimus, Basiliximab, Tacrolimus, Dapagliflozin, Verinurad, Allopurinol, BAY3283142
• Launching multiple stage Chronic Kidney Disease pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Chronic Kidney Disease market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Chronic Kidney Disease Overview:
According to the NIDDK, chronic kidney disease (CKD) is a condition where the kidneys are damaged and can't filter blood the way they should, and these abnormalities of kidney structure or function are present for >3 months, with implications for health. Clinically it is defined as the presence of kidney damage or an estimated glomerular filtration rate less than 60 mL/min/1.73 mt2, persisting for 3 months or more, irrespective of the cause. It is a state of progressive loss of kidney function.

Chronic Kidney Disease Epidemiology Segmentation:
The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Chronic Kidney Disease Total Diagnosed Prevalent Cases
• Chronic Kidney Disease Gender-specific Diagnosed Cases
• Chronic Kidney Disease Age-specific Diagnosed Cases
• Chronic Kidney Disease Stage-specific Diagnosed Cases

For more information about Chronic Kidney Disease companies working in the treatment market, visit https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Chronic Kidney Disease Market Insights
The global Chronic Kidney Disease market has witnessed steady growth due to the rising prevalence of CKD and associated conditions like diabetes and hypertension. As of recent estimates, the CKD market is expected to grow at a CAGR of 6-8% over the next several years, reaching a multi-billion-dollar valuation by 2030. Major drivers include an aging global population, advancements in diagnostic tools, and the introduction of novel therapeutics aimed at slowing disease progression.

Chronic Kidney Disease Drugs Uptake
• Sodium-glucose co-transporter-2 (SGLT2) Inhibitors: Dapagliflozin (Farxiga) and canagliflozin (Invokana) are leading drugs in this class, initially developed to treat diabetes but now widely used for CKD management due to their proven benefits in slowing disease progression and reducing cardiovascular risk.
• Non-Steroidal Mineralocorticoid Receptor Antagonists (MRAs): Finerenone (Kerendia) has gained significant attention for its ability to reduce the risk of CKD progression in patients with diabetes. Its non-steroidal nature offers advantages over traditional MRAs, minimizing adverse effects such as hyperkalemia.
• Endothelin Receptor Antagonists: Atrasentan, in development, is showing promise in clinical trials for CKD management, particularly in diabetic kidney disease. Its unique mechanism targets endothelin, a protein involved in inflammation and fibrosis in CKD.
• Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) continue to be the standard of care for CKD patients, particularly in controlling blood pressure and reducing proteinuria.
• Bardoxolone Methyl: A novel anti-inflammatory agent showing promise in delaying CKD progression in multiple trials, particularly for patients with Alport syndrome, a rare genetic form of CKD.
• Roxadustat: A hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to treat anemia in CKD patients. It offers an oral alternative to ESAs and is in various stages of regulatory approval.
• Sparsentan: A dual-acting angiotensin receptor blocker and endothelin receptor antagonist, it is showing positive results in treating rare kidney diseases such as IgA nephropathy and focal segmental glomerulosclerosis (FSGS).

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Chronic Kidney Disease Therapies and Key Companies:
• MK0954: Organon and Co
• epoetin: Johnson & Johnson
• PF-00489791, Fragmin: Pfizer
• OPC-41061: Otsuka Pharmaceutical Co., Ltd.
• Renamezin: Daewon Pharmaceutical Co., Ltd.
• sitagliptin, glipizide: Merck Sharp & Dohme LLC
• cinacalcet: Amgen
• HD-003: Hyundai Pharmaceutical Co., LTD.
• Atrasentan: Chinook Therapeutics, Inc.
• Everolimus, Basiliximab, Tacrolimus: Novartis Pharmaceuticals
• Dapagliflozin, Verinurad, Allopurinol: AstraZeneca
• BAY3283142: Bayer

Chronic Kidney Disease Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Chronic Kidney Disease.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Chronic Kidney Disease Market Drivers:
• Increasing Prevalence of CKD
• Aging Population
• Novel Therapeutic Developments
• Growing Awareness and Screening

Chronic Kidney Disease Market Barriers:
• High Treatment Costs
• Limited Access to Healthcare
• Underdiagnosis
• Stringent Regulatory Requirements

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Chronic Kidney Disease Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Chronic Kidney Disease Companies: ProKidney, Reata Pharmaceuticals, Inc.,Novo Nordisk A/S, Boehringer Ingelheim,Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc, Lexicon Pharmaceuticals, Sanofi
• Key Chronic Kidney Disease Therapies: MK0954, epoetin, PF-00489791, Fragmin, OPC-41061, Renamezin, sitagliptin, glipizide, cinacalcet, HD-003, Atrasentan, Everolimus, Basiliximab, Tacrolimus, Dapagliflozin, Verinurad, Allopurinol, BAY3283142
• Chronic Kidney Disease Therapeutic Assessment: Current marketed and emerging therapies
• Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease Market drivers and Chronic Kidney Disease barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Kidney Disease Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Chronic Kidney Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. CKD Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Key Events
6. Executive Summary of of CKD
7. Disease Background and Overview of Chronic Kidney Disease (CKD)
8. Epidemiology and Patient Population of CKD
9. Patient Journey
10. Marketed Drugs
11. Emerging Drugs
12. CKD: Seven Major Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.